These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23766490)

  • 21. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae.
    Muratani T; Matsumoto T
    Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S10-3. PubMed ID: 16829056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
    Harada S; Ishii Y; Yamaguchi K
    Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06.
    Livermore DM; Hope R; Brick G; Lillie M; Reynolds R;
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii55-63. PubMed ID: 18819980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ; van Mil AC; Mouton JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
    Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N
    Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
    Etienne M; Van Elslande H; Choplin-Renard J; Pestel-Caron M; Caron F
    Med Mal Infect; 2014 May; 44(5):217-22. PubMed ID: 24787633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in resistance among coliform bacteraemia associated with a primary care antimicrobial stewardship intervention: A population-based interrupted time series study.
    Hernandez-Santiago V; Davey PG; Nathwani D; Marwick CA; Guthrie B
    PLoS Med; 2019 Jun; 16(6):e1002825. PubMed ID: 31173597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotypic analysis of plasmid-mediated beta-lactamases amongst Enterobacteriaceae other than Escherichia spp. and Klebsiella spp. that are non-susceptible to a broad-spectrum cephalosporin.
    Kiratisin P; Henprasert A
    Int J Antimicrob Agents; 2010 Oct; 36(4):343-7. PubMed ID: 20688485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    Int J Antimicrob Agents; 2017 Feb; 49(2):239-242. PubMed ID: 27939093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
    Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
    Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM; Shier KL; Graber CJ
    J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relentless increase of resistance to fluoroquinolones and expanded-spectrum cephalosporins in Escherichia coli: 20 years of surveillance in resource-limited settings from Latin America.
    Bartoloni A; Pallecchi L; Riccobono E; Mantella A; Magnelli D; Di Maggio T; Villagran AL; Lara Y; Saavedra C; Strohmeyer M; Bartalesi F; Trigoso C; Rossolini GM
    Clin Microbiol Infect; 2013 Apr; 19(4):356-61. PubMed ID: 22414066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.